Jupiter Neurosciences Launches Nugevia MND Cognitive Health Supplement

Jupiter Neurosciences, a drug platform company that has developed a resveratrol ingredient called Jotrol, has launched Nugevia MND, a dietary supplement formulated to enhance cognitive function and support overall brain health.

The supplement features Jupiter’s proprietary Jotrol resveratrol technology, which is more bioavailable and is validated to penetrate the nervous system, and NovaSol Curcumin, a bioavailable curcumin formulation evidenced to support cognitive resilience and neuroprotection.

This pairing targets multiple neuroprotective pathways and is designed to reduce oxidative stress, modulate inflammation, and support synaptic plasticity, all to promote enhanced cognitive health.

“We’ve worked extensively on our third, and, in my opinion, most important product in the Nugevia launch,” said Christer Rosén, chairman and CEO of Jupiter Neurosciences. “My mother passed away from Alzheimer’s disease, making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s disease. This is personal, this is important, and, based on our Jotrol pharmaceutical pre-clinical and clinical data, we are here to bring what we believe is the best cognition product to the market.”

“The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market,” said Rosén. “Importantly, learnings from our consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs. What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.”

The dietary supplement, Nugevia MND, was made to complement Jupiter’s therapeutic pipeline, creating synergy between its consumer-grade and pharmaceutical segments.

The product is marketed with claims including:

• Enhanced memory, clarity, and executive function
• Reduction in neuroinflammation and oxidative stress
• Support for mitochondrial function in brain cells
• Potential protective effects against age-related cognitive decline

“MND not only reinforces our dual-path business strategy but also provides an immediate opportunity for revenue growth and meaningful data collection,” Rosén said. “Investors can be excited about the implications of a consumer product directly supporting our pharmaceutical development pipeline.”

The supplement, which is intended to be taken via two daily capsules, will be available via e-commerce platforms and direct-to-consumer in the fall.